Show simple item record

dc.contributor.authorAlonso Monsalve, Rodrigo
dc.contributor.authorRodríguez Achaerandio, Ainara
dc.contributor.authorAguirre Quiñonero, Amaia
dc.contributor.authorArtetxe, Aitor
dc.contributor.authorMartínez Ballesteros, Ilargi ORCID
dc.contributor.authorRodríguez Gascón, Alicia
dc.contributor.authorGaraizar Candina, Javier ORCID
dc.contributor.authorCanut Blasco, Andrés
dc.date.accessioned2021-10-27T10:04:49Z
dc.date.available2021-10-27T10:04:49Z
dc.date.issued2021-10-15
dc.identifier.citationPharmaceutics 13(10) : (2021) // Article ID 1699es_ES
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10810/53647
dc.description.abstractThe aim of this study was to apply molecular epidemiology, antimicrobial surveillance, and PK/PD analysis to guide the antimicrobial treatment of gonococci infections in a region of the north of Spain. Antibiotic susceptibility testing was performed on all isolates (2017 to 2019, n = 202). A subset of 35 isolates intermediate or resistant to at least two antimicrobials were selected to search for resistance genes and genotyping through WGS. By Monte Carlo simulation, we estimated the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of the antimicrobials used to treat gonorrhea, both indicative of the probability of treatment success. In total, 2.0%, 6.4%, 5.4%, and 48.2% of the isolates were resistant to ceftriaxone, cefixime, azithromycin, and ciprofloxacin, respectively. Twenty sequence types were identified. Detected mutations were related to antibiotic resistance. PK/PD analysis showed high probability of treatment success of the cephalosporins. In conclusion, multiple populations of N. gonorrhoeae were identified. We can confirm that ceftriaxone (even at the lowest dose: 250 mg) and oral cefixime are good candidates to treat gonorrhea. For patients allergic to cephalosporins, ciprofloxacin should be only used if the MIC is known and ≤0.125 mg/L; this antimicrobial is not recommended for empirical treatment.es_ES
dc.description.sponsorshipThis research was funded by the University of the Basque Country UPV/EHU (GIU20/048; PA20/03), Spain.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectN. gonorrhoeaees_ES
dc.subjectantibiotic resistancees_ES
dc.subjectcephalosporinses_ES
dc.subjectazithromycines_ES
dc.subjectpharmacokinetic/pharmacodynamic (PK/PD) analysises_ES
dc.subjectwhole-genome sequencing (WGS)es_ES
dc.titleMolecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of Neisseria gonorrhoeae Infectionses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-10-22T13:56:03Z
dc.rights.holder2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/10/1699/htmes_ES
dc.identifier.doi10.3390/pharmaceutics13101699
dc.departamentoesInmunología, microbiología y parasitología
dc.departamentoeuImmunologia, mikrobiologia eta parasitologia


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).